Search Details

Word: treates (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

...trainee--but one with a rocket strapped to his back. A year after joining Sandoz, Vasella became product manager for a new drug named Sandostatin, approved to treat a rare pancreatic cancer. The head of Sandoz's U.S. pharmaceutical unit joked that Vasella could consider his job well done if he made Sandostatin a $5 million product, a pittance in the branded-drug business. Vasella realized that to make Sandostatin a commercial success, he had to find new uses for it. And he believed he could do that only by radically changing the game...

Author: /time Magazine | Title: Drug Lord | 11/13/2007 | See Source »

Such drugs can also have other applications. That's what guides Novartis' continuing research on Gleevec, a revolutionary drug initially directed against a rare leukemia. Responding to petitions from patients, Vasella pushed to complete clinical trials of the drug in just 32 months. It was recently approved to treat a second rare cancer that affects the stomach. Now Novartis is evaluating its effects in combination with other drugs on more common cancers, such as those of the prostate...

Author: /time Magazine | Title: Drug Lord | 11/13/2007 | See Source »

ADHD is the most common psychiatric childhood disorder in the United States, but it's not bound by geography; diagnosis of ADHD is increasing globally. Since 1993, use of stimulant drugs to treat ADHD has more than tripled worldwide, according to one study. Symptoms for the disorder include impulsiveness, hyperactivity and poor concentration, and can develop over several months. Though most people outgrow the hyperactivity aspect - characterized by having trouble sitting still, moving around when others are seated, or talking while others are talking - about a quarter to a third of children and teenagers carry their ADHD into adulthood. Some...

Author: /time Magazine | Title: ADHD Kids Can Get Better | 11/12/2007 | See Source »

...Americans spend to rejuvenate their faces and remove unwanted hair. Seeing synergies with its Neutrogena brand, J&J jumped into self-dermatology in 2004, signing an exploratory multiyear licensing deal with the $120 million company Palomar Medical Technologies to develop, test and commercialize light-based aesthetic devices that can treat wrinkles, cellulite and acne. "We have the potential to penetrate a good part of that market," says Palomar's chief financial officer, Paul Weiner--but so far no commercial product...

Author: /time Magazine | Title: Cosmetics: The Newest Wrinkle | 11/12/2007 | See Source »

...Avon have for several years been selling souped-up scrubs and exfoliators billed as microdermabrasion kits, and antiwrinkle creams that mimic the effects of dermatologist-delivered aesthetic fillers, this is different. These new treatments are scaled-down versions of the light-based devices used by dermatologists to treat skin ailments, all designed so that a consumer can use them. Even hair removal via an at-home laser is on the table. Leading the way: Zeno and ThermaClear, two FDA-approved antiacne devices already on store shelves. Most other products are still in development. "This trend is going to change...

Author: /time Magazine | Title: Cosmetics: The Newest Wrinkle | 11/12/2007 | See Source »

Previous | 133 | 134 | 135 | 136 | 137 | 138 | 139 | 140 | 141 | 142 | 143 | 144 | 145 | 146 | 147 | 148 | 149 | 150 | 151 | 152 | 153 | Next